Business
* MedImmune Inc. will buy cancer drug maker U.S.
Sept. 23, 1999
AstraZeneca, struggling to develop new medicines, said Monday that it agreed to buy biotechnology company MedImmune Inc. for $15.2 billion in cash to gain flu vaccines and an antiviral treatment for babies.
April 24, 2007
Technology and the Internet
MedImmune Inc. agreed to buy vaccine maker Aviron in a bid to add FluMist, Aviron’s promising treatment for influenza, to its own portfolio of drugs for infectious diseases.
Dec. 4, 2001
The U.S.
Jan. 10, 2007
Xencor secures $45 million from MedImmune, part of a trend of alliances between start-ups and bigger players.
Oct. 20, 2006
MedImmune Inc. received Food and Drug Administration approval to sell RespiGam to reduce respiratory infections in certain high-risk infants. . . .
Jan. 20, 1996
Apparently, biotechnology stocks might be just the cure for what ails some investors: fear of exposure to foreign markets.
Sept. 3, 1998
MedImmune alleges the rights to a method of making antibodies were gained in an illegal deal.
May 3, 2003
A judge has ruled that MedImmune Inc. cannot pursue antitrust claims in its suit to invalidate a patent controlled by Genentech Inc. for the method to create drugs using antibody molecules to fight diseases.
Dec. 27, 2003
Science & Medicine
Pharmaceuticals: FDA has 68 questions on clinical and manufacturing data for MedImmune’s FluMist.
July 12, 2002